BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/20/2014 10:04:00 AM | Browse: 1356 | Download: 1124
Publication Name World Journal of Hematology
Manuscript ID 10025
Country/Territory Japan
Received
2014-03-09 17:10
Peer-Review Started
2014-03-10 08:45
To Make the First Decision
2014-04-28 14:34
Return for Revision
2014-04-30 15:00
Revised
2014-05-09 16:37
Second Decision
2014-06-18 14:58
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-06-18 15:17
Articles in Press
2014-06-18 15:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-06-24 03:01
Typeset the Manuscript
2014-09-28 17:48
Publish the Manuscript Online
2014-10-20 10:04
ISSN 2218-6204 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Hematology
Manuscript Type Review
Article Title Hemophagocytic lymphohistiocytosis: Recent progress in the pathogenesis, diagnosis and treatment
Manuscript Source Invited Manuscript
All Author List Shinsaku Imashuku
Funding Agency and Grant Number
Corresponding Author Shinsaku Imashuku, MD, PhD Consultant to the Department of Laboratory Medicine, Uji-Tokushukai Medical Center 86 Kasugamori, Ogura-cho, Uji, Kyoto, Japan 611-0042 Tel: +81-774-20-1111; FAX +81-0774-20-2336 E-mail: shinim95@mbox.kyoto-inet.or.jp
Key Words hemophagocytic lymphohistiocytosis; ; molecular diagnosis; hematopoietic stem-cell transplantation; cyclosporine A; rituximab
Core Tip This review discusses the diagnostic criteria for HLH, the algorithms used to identify the underlying immune defects at the molecular level, and the optimal therapeutic approaches. For any HLH cases, a screening for primary HLH should be made following the diagnostic algorithm. During the process, immunosuppressive therapy should be started to control the hypercytokinemia with steroids, CSA, or IVIG, and if primary HLH is confirmed, immunochemotherapy with a regimen containing etoposide or ATG should be given. Supportive measures to control hemorrhage/organ dysfunction are also required. In cases of primary HLH or secondary/refractory HLH, timely allogeneic hematopoietic stem-cell transplantation is recommended.
Publish Date 2014-10-20 10:04
Citation Imashuku S. Hemophagocytic lymphohistiocytosis: Recent progress in the pathogenesis, diagnosis and treatment. World J Hematol 2014; 3(3): 71-84
URL http://www.wjgnet.com/2218-6204/full/v3/i3/71.htm
DOI http://dx.doi.org/10.5315/wjh.v3.i3.71
Full Article (PDF) WJH-3-71.pdf
Full Article (Word) WJH-3-71.doc
Manuscript File 10025-Review.docx
Answering Reviewers 10025-Answering reviewers.pdf
Copyright License Agreement 10025-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate Editing_Certificate_20140309092311.pdf
Peer-review Report 10025-Peer review(s).pdf
Scientific Misconduct Check 10025-CrossCheck.jpg
Scientific Editor Work List 10025-Scientific editor work list.pdf